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Antigen-Specific CD8þ Tumor-Reactive T-Cell
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Fre´de´rique-Anne Le Gal1,2, Vale´rie M. Widmer1, Vale´rie Dutoit3, Verena Rubio-Godoy3, Jacques Schrenzel4,
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Tumor antigen-specific cytotoxic T cells (CTLs) play a major role in the adaptive immune response to cancers.
This CTL response is often insufficient because of functional impairment, tumor escape mechanisms, or
inhibitory tumor microenvironment. However, little is known about the fate of given tumor-specific CTL clones
in cancer patients. Studies in patients with favorable outcomes may be very informative. In this longitudinal
study, we tracked, quantified, and characterized functionally defined antigen-specific T-cell clones ex vivo, in
peripheral blood and at tumor sites, in two long-term melanoma survivors. MAGE-A10-specific CD8þ T-cell
clones with high avidity to antigenic peptide and tumor lytic capabilities persisted in peripheral blood over
more than 10 years, with quantitative variations correlating with the clinical course. These clones were also
found in emerging metastases, and, in one patient, circulating clonal T cells displayed a fully differentiated
effector phenotype at the time of relapse. Longevity, tumor homing, differentiation phenotype, and quantitative
adaptation to the disease phases suggest the contribution of the tracked tumor-reactive clones in the tumor
control of these long-term metastatic survivor patients. Focusing research on patients with favorable outcomes
may help to identify parameters that are crucial for an efficient antitumor response and to optimize cancer
immunotherapy.
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INTRODUCTION
Tumor antigen-specific CD8þ T-cell responses have been
widely documented in cancer patients. However, given the
complexity of the interactions between the tumor and the
immune system, the existence of circulating tumor-specific
CD8þ T cells does not per se imply that they are efficient in
fighting the tumor. Indeed, tumor antigen-specific T-cell
responses are often observed in patients with advanced
disease without any sign of cancer regression, and sometimes
the frequency and the amplitude of the response can even be
positively correlated with tumor progression (Letsch et al.,
2000). In order to control the disease, antigen-specific T cells
should be functionally active, that is, tumor lytic, able to
home to the tumor sites, not inhibited by the tumoral
microenvironment or rendered ineffective by the escape
mechanisms developed by tumor cells. Such criteria may be
met in rare patients with favorable clinical outcome who
develop antitumor immune responses, either spontaneously
or after treatment. Careful examination of such cases could
help in understanding the parameters that are crucial for an
antitumor immune response to be clinically efficient.
Here, we took advantage of the long medical follow up
(more than 10 years) of two melanoma patients, surviving an
aggressive disease, in whom we previously reported two
dominant HLA-A2/MAGE-A10 tumor-reactive clones at a
given time point (Dutoit et al., 2001). By tracking these
tumor-specific CD8þ T-cell clones in a longitudinal analysis,
we show (i) their persistence in the blood over 10 years,
(ii) their presence in melanoma involved tissues, (iii) substantial
variation in their frequency throughout the clinical course,
and (iv) the clinical circumstances of their activation.
RESULTS
Clinical data
LAU 50 is a 62-year-old HLA-A2þ patient with a primary
malignant melanoma (Breslow: 4.3 mm) of the right limb that
was surgically excised in October 1992. Multiple in-transit
metastases (n¼ 31) appeared between January and July 1993.
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Isolated limb perfusion (ILP) of Melphalan plus tumor
necrosis factor-a and IFN-g induced a complete remission
for 2 years. In June 1995, a right inguinal metastatic lymph
node was surgically removed and the patient did not relapse
for 8.5 years. In December 2003, an inguinal lymph node
metastasis was revealed by positron emitting tomography
scan and surgically removed (Figure 1a, left panel). He
entered a multipeptide vaccine trial in January 2004 and is
still disease free today.
LAU 155 is a 50-year-old HLA-A2þ patient, diagnosed
with a facial primary malignant melanoma (Breslow:
2.62 mm) in 1993. He received an experimental adjuvant
ganglioside vaccine but no specific antibodies were induced,
and treatment was discontinued after 3 months. In 1994, he
developed axillary lymphatic and hepatic metastases, which
were confirmed by needle biopsies. He was included in a
pilot trial investigating the combination of cis-platinum, IL-2
and IFN-g. Four cycles of this treatment were administered,
inducing the complete regression of the lymph node
metatases. Given a persisting image of hepatic nodule on
computed tomography scan, a partial hepatectomy was
performed. Pathological examination revealed a tumor-free
cicatricial nodule. This stage IV melanoma patient is still
tumor free 11 years after diagnosis, whereas his expected
survival time was only 6–9 months in 1995 (Eton et al., 1998)
(Figure 1a, right panel). In 1994, after start of chemo-
immunotherapy, he presented with vitiligo. In melanoma
patients, this kind of skin depigmentation reflects melanocyte
destruction mediated by T cells directed toward antigens
shared by melanoma cells and normal melanocytes (Le Gal
et al., 2001), with increased incidence in individuals who
respond to immunotherapy (Le Gal et al., 1996; Rosenberg
and White, 1996; Phan et al., 2001).
Long-term persistence of unique T-cell clones in the
MAGE-A10254–262-specific CD8
þ T-cell response in vitro
Considering the long-term favorable outcome of melanoma
patients LAU 50 and LAU 155, it was interesting to follow
tumor-specific T-cell responses in a longitudinal study. We
focused on the MAGE-A10 tumor antigen, based on previous
experiments that identified MAGE-A10254–262-specific CD8
þ
T-cell responses in both patients (Valmori et al., 2001).
Nevertheless, as observed in a series of patients with
spontaneous MAGE-A10-specific T-cell response (Dutoit
et al., 2001; Valmori et al., 2001), the low ex vivo frequency
of MAGE-A10-specific CD8þ T cells in peripheral blood
precluded direct multimer-guided cell sorting. Thus, in order
to obtain MAGE-A10-specific T cells in sufficient quantity for
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Figure 1. Ex vivo detection of MAGE-A10-specific T-cell clones 15 and 6D1 in peripheral blood and tissues along the clinical course of patients LAU 50 and
LAU 155. (a) Schematic representation of the clinical course of patients LAU 50 (left panel) and LAU 155 (right panel). (b) Quantification of the transcripts
of clonotype 15 (left panel) and clonotype 6D1 (right panel) in peripheral CD8þ T cells by real-time quantitative reverse transcriptase-PCR. Values are
shown as the ratio of the calibrated expression of the CDR3 transcripts normalized to the expression of the TRBC transcripts. SDs of replicates were inferior
to 2.5% of the value for each time point. Background level is illustrated. Available tissues (indicated by symbols) were also investigated for the presence of
clonotypes 15 (left panel) and 6D1 (right panel).
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thorough molecular and functional analysis, peripheral blood
mononuclear cells (PBMCs) from LAU 50 (from 1993 to
2000) and LAU 155 (from 1997 to 2000) were stimulated
in vitro for 2 weeks with the cognate peptide, and MAGE-
A10254–262-specific CD8
þ T cells were then isolated by
multimer-guided cell sorting (Dutoit et al., 2001). The TCR
diversity of MAGE-A10-specific CD8þ T cells was assessed
using classical complementarity determining region 3 (CDR3)
size analysis of BV1-BV24 amplified transcripts (Dietrich
et al., 2001). For most TCR b-chain variable region (BV)
subsets, we did not observe any significant signal, suggesting
a restricted MAGE-A10 TCR repertoire (at least in vitro).
In both patients, dominant peaks could be observed in certain
BV transcripts, but only at some time points (e.g. BV4). In
contrast, a major BV21 peak of constant CDR3 size was
observed over several years, corresponding to 9 and 8 aa in
samples from LAU 50 and LAU 155, respectively (Figure 2).
Despite a possible bias induced by the 2-week in vitro
stimulation, such identical profiles recurring at different time
points strongly suggested the presence of unique MAGE-
A10254–262-specific CD8
þ T-cell clones persisting in the
peripheral blood of both patients. Molecular cloning and
sequencing of the BV21 transcripts confirmed the mono-
clonality of each sample (with the exception of a second
minor clone in LAU 155 – 1999). Moreover, the same
recurrent sequence was observed in the BV21 samples from
1997 to 2000 for LAU 155. For LAU 50, the MAGE-A10-
specific CD8þ T-cell clone that was dominant at the
beginning of the disease was definitively replaced since
1997 by another one with the same CDR3 size (Figure 2).
Interestingly, the recurrent CDR3 sequences were those
expressed by two BV21 MAGE-A10 CD8þ T-cell clones
(SFGGLGYEQ for clone LAU 50/15 and SLEYTGEL for clone
LAU 155/6D1) we previously derived from peripheral blood
lymphocytes and tumor infiltrating lymphocytes in those
patients (Dutoit et al., 2001). Both clones displayed high
avidity of MAGE-A10 peptide recognition and strong lytic
capacity of A2/MAGE-A10-expressing melanoma cells
(Dutoit et al., 2001).
Longitudinal ex vivo quantification of the MAGE-A10-specific
prominent clones in peripheral blood
Cellular cloning (Dutoit et al., 2001) and molecular TCR-BV
repertoire analysis (this study) both led to the identification of
a unique prominent and persistent MAGE-A10-specific
CD8þ T-cell clone with high tumor reactivity in each
patient. However, these clones were identified after in vitro
culture, which may not necessarily expand cells with
biological relevance in vivo. Thus, we directly tracked and
quantified both clones (clone 6D1 for LAU 155, clone 15 for
LAU 50) in ex vivo unstimulated CD8þ T cells from serial
blood samples, using real-time reverse transcriptase-PCR of
their clonotypic transcripts. The quantitative expression of the
clonotype was normalized to the quantitative expression of
the TCR b-chain constant region (TRBC). Such an endogen-
ous control avoids the variations of expression that occur
with housekeeping genes. The level of transcription of the
TRBC parallels that of the variable region of this chain, so that
fluctuations in TCR turnover should not alter the relative
quantification of the clonotype among T cells. As in previous
T-cell clonotype tracking studies (Douek et al., 2002; Muraro
et al., 2003), serial dilutions showed that the limit of
detection of this assay was about 10 clonotype cells in 106
PBMC, for both clones (data not shown). For LAU 155, blood
samples were available from 1995 to 2004 (Figure 1b, right
panel). Clone 6D1 was detected ex vivo at each time point
analyzed, with a low and quite stable frequency over the
background level. It was noteworthy that all blood samples
were collected when the patient was in persisting complete
remission (since May 1995), a clinical setting that could play
a role in the low amount and the stability of this clone in the
peripheral blood.
Contrasting results were observed with LAU 50, for whom
blood samples were available over a long period of time (11
years) not only during clinical remission but also before and
after relapse (Figure 1b, left panel). Indeed, whereas the
clonotype 15 expression was weak or sometimes below the
detection threshold during a long period of remission
(1994–2001), high expression was observed at other time
points. A first peak of expression was seen in the 1993
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Figure 2. Longitudinal TCR repertoire analysis of MAGE-A10254–262-specific
CD8þ T cells. After 2 weeks of in vitro stimulation with peptide
MAGE-A10254–262, LAU 50 and LAU 155 MAGE-A10 CD8
þ -specific
T cells were sorted and their TCR b-chain V segment usage and CDR3 length
were assessed by spectratyping. Total RNA was extracted from each sample,
reversed transcribed, and amplified by PCR using BV and BC primers.
Amplimers were copied by a fluorescent BC primer in a run off reaction and
subjected to electrophoresis on an automated sequencer. The curves obtained
show the size and intensity distribution of in-frame BV–BC amplification
products. BV4 and BV13 are representative of most of the longitudinal
repertoire (i.e. no amplification, inconstant isolated peaks of various sizes,
and oligoclonal profiles). Only BV21 products displayed peaks of the same
size recurring at each time point. BV21 transcripts were sequenced after
molecular cloning. The occurrence of the sequences is indicated.
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sample, 10 months after excision of the primary tumor but
only 1 month after ILP. A second major peak was observed in
2002–2003, when the frequency of clonotype 15 abruptly
increased and then progressively returned to baseline,
preceding the detection by positron emitting tomography
scan of an infraclinical metastatic lymph node. Importantly,
expression of MAGE-A10 was confirmed by PCR on each
tumor sample until 2004 (data not shown). Unfortunately, no
blood sample was available at the time of the lymphatic
relapse in 1995.
Ex vivo detection of the MAGE-A10-specific clones at tumor
sites
The systemic circulation of tumor-reactive clones suggests
their possible role in tumor immunosurveillance. However,
their capacity to infiltrate tumor sites is critical to control
disease. To determine whether tumor infiltration occurred,
we directly tracked these clones ex vivo in formalin-fixed
tumor tissues from both patients using clonotypic quantitative
real-time PCR (qRT-PCR) (Figure 1b). In LAU 50, clonotype
15 was detected by qRT-PCR in the metastatic lymph node
excised in 1995, that is, 3 years after the diagnosis of the
primary tumor. Clone 15 was also detected in the second
metastatic lymph node excised in 2004. In contrast, it was
neither detectable in non-metastatic lymph nodes
(1992–1993), nor in the primary tumor (1992) nor in the
sub-cutaneous metastases (1993), each of those samples
having been collected before ILP. This could suggest a role of
ILP in eliciting a MAGE-A10-specific response. In LAU 155, a
liver metastasis appeared in 1994, 1 year after the excision of
the primary tumor. The diagnosis of melanoma metastasis
was confirmed by histological analysis of a needle biopsy that
also revealed a substantial CD8þ T-cell infiltrate (Figure 3,
left, upper row). Chemo-immunotherapy was delivered, and
end-treatment computed tomography scan showed a residual
nodule. A partial hepatectomy was performed, which
revealed a tumor-free fibrous nodule, which was surrounded
by lymphocytes, mostly CD8þ T cells (Figure 3, left, lower
row). The absence of tumor cells was assessed by examina-
tion of serial sections of the excised fibrous nodule, and by
reverse transcriptase-PCR (data not shown). Using qRT-PCR,
clone 6D1 was found in both pre- and post-treatment liver
samples (Figure 3, right panels), showing that tumor-specific
T cells may persist in the absence of detectable tumor cells
after a therapeutic intervention. Overall, the data in both
patients indicate that tumor-specific clones have infiltrated
the tumor sites, at least since the onset of the metastatic
process.
Phenotype of MAGE-A10-specific T-cell clone during clinical
course
As previously noted, the functional properties of circulating
clone 15 (LAU 50) and clone 6D1 have already been assessed
in vitro (Dutoit et al., 2001), which motivated our choice to
track these clones ex vivo. Considering that the frequency of
MAGE-A10-specific CD8þ T cells was too low for direct
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Figure 3. Detection of clone 6D1 in liver samples before and after chemo-immunotherapy. Left panels: CD8 staining in a needle biopsy of melanoma liver
metastasis before biochemotherapy in 1994 (upper row) and in a tumor-free piece of liver excised after biochemotherapy in 1995 (lower row), showing
persistent lymphocytic infiltrate (L.I.) predominant in the cicatricial nodule. Sections (5mm) of paraffin-embedded tissue have been stained with an anti-CD8
mAb and counterstained with hemalun. Original magnification  100. Bar¼ 0.25 mm. Right panels: real-time quantitative reverse transcriptase-PCR detection
of clonotype 6D1 in the related tissue samples. Total RNA was extracted and reverse transcribed with an oligodT primer (frozen tissue 1995) or with a
BV21-specific primer (fixed tissue 1994). cDNA was assayed in duplicate using probe/primer set specific for the clonotype. CT values were superior to 40
for no template controls (NTC).
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multimer detection and sorting, direct functional analysis of
these clones ex vivo was not possible. We therefore used
another approach by sorting circulating CD8þ T cells with
naive, effector or memory phenotypes (according to the
differential expression of the CCR7 and CD45RA molecules
(Sallusto et al., 1999)) and quantifying the clonotypes within
these sub-populations. Two time points, corresponding to
distinct disease status, were analyzed in patient LAU 50
(Figure 4). Whereas clone 15 was only faintly detectable in
each sorted sub-population during complete remission
(1997), a considerable increase of the clone’s frequency was
observed 6 months before the clinical detection of tumor
relapse (2003) in the fully differentiated effector sub-population.
DISCUSSION
In the last two decades, major advances have been made in
the understanding of tumor immunity, mainly thanks to basic
research performed in well-defined animal models. How-
ever, the direct extrapolation (at least for therapeutic
purposes) of new concepts elucidated in simplified models
toward the more complicated field of human tumors was
often disappointing. In humans, most studies exploring the
interactions between tumor cells and the immune system
have been performed in the context of tumor progression,
that is, when the protective role of the immune system has
failed or was circumvented. Therefore, it is not surprising that
research performed in this clinical context led to the
discovery of a multitude of immune evasion mechanisms
(Marincola et al., 2003), but was poorly informative about the
critical parameters required for an effective antitumor
immune response. More useful in this objective could be
the study of patients with spontaneous or treatment-induced
favorable outcome. Several obstacles have limited this
research area: (i) whatever the treatment, tumor control is
rare in metastatic patients, (ii) favorable outcome implies a
reduced availability of tumor material (iii) for practical and
economic reasons, blood and tissue sampling is rarely
systematic.
In this study, we had the rare opportunity to study
antitumor immune responses over a long period of time in
two melanoma patients with favorable but distinct outcomes:
LAU 155 never relapsed after hepatic metastasis, whereas
LAU 50 relapsed three times, giving us the chance to
compare two different situations. Based on previous data
(Dutoit et al., 2001; Valmori et al., 2001), we focused on
MAGE-A10-specific CD8þ T-cell clones, and followed their
course over a 10- to 12-year period, using combined
molecular and cellular methods optimized to be used with
small amounts of biological material. This had the advantage
of providing a dynamic view of events that are usually studied
at one isolated time point.
The most direct finding coming from this longitudinal
analysis is the demonstration of the capacity of defined
tumor-specific CTL clones to persist long term, that is, at least
10 years in LAU 155 and 12 years in LAU 50. Whereas long-
term persistence of clonal T cells has been reported in various
autoimmune and infectious diseases (Goebels et al., 2000;
Lim et al., 2000; Posavad et al., 2000; Hofbauer et al., 2003),
there were fewer instances reported in melanoma patients. In
ex vivo analysis, Schrama et al. (2001) showed the
persistence of some HLA-A2-restricted Melan-A- and
gp100-reactive T-cell clones over 5 months. More recently
survivin-specific T cells were reported to persist up to 7 years
in a patient after immunotherapy (Hadrup et al., 2006).
Despite the lack of clonality analysis, these data reinforce our
observation of persistent CTL reactivity in long-term survi-
vors. Thus, such lasting tumor-specific T cells may have
played a role in the favorable outcome of the two studied
patients, considering the importance of persistence of
antitumor T cells in the control of the disease, as recently
demonstrated in the setting of adoptive immunotherapy
(Robbins et al., 2004).
The mechanism that underlies the long persistence of the
tumor-specific clones in our two patients is not directly
addressed in this work. During the tumor-free periods, we
can hypothesize that homeostatic proliferation is the main
mechanism implied in the maintenance of these high-avidity
clones. This is supported by recent observations showing that
high-avidity of antigen recognition is critical to allow long-
term persistence of CD8þ T cells by homeostatic prolifera-
tion (Lim et al., 2000; Oh et al., 2004). On the other hand,
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cells from each of the four CD8þ T-cell sub-populations were sorted for
further analysis in qRT-PCR. A representative example of two cell sorting
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antigenic stimulation could explain the peaks of frequency of
clone 15 in 1993 and 2002–2003 in LAU 50: at these two
time points, resurgence of tumor cells (still expressing MAGE-
A10, data not shown) may stimulate the proliferation of clone
15. In 2002, proliferation of clone 15 was probably
stimulated by the presence of undetectable tumor cells that
finally emerged, as clone 15 disappeared from the peripheral
blood (but remained present in situ). This observation could
indicate that weakening of the clone 15-mediated antitumor
response allowed the tumor cells to proliferate. This failure
could be due to various mechanisms of tumor escape, and in
particular, to impairment of the effector functions of this
clone in vivo. Unfortunately, given its low frequency, ex vivo
sorting of this clone was not possible, precluding direct
investigation of this question.
Peaks of proliferation of clone 15 can be the result of the
differentiation of effector memory cells into fully differen-
tiated effector cells, or of the stimulation of central memory
cells as a secondary response (Sallusto and Lanzavecchia,
2001). Nevertheless, circulating fully differentiated specific
effector cells with conserved proliferative capacities have
been reported in melanoma patients with either stabilized or
progressing disease (Valmori et al., 2002), so we cannot
exclude that the increased frequency of clone 15 in 2003
directly results from the proliferation of a persistent small
pool of terminally differentiated clone 15 effector cells.
Homing of CTL clones to the tumor site is a requisite to
control the disease. Because of technical difficulties, this
point is not sufficiently addressed in vaccine trials. Also in our
study, cell sorting and functional assays could not be
performed on archived tumor samples. However, tracking
defined T-cell clones can be performed with qRT-PCR, even
with very small biopsies and formalin-fixed material. Using
this approach, we showed the homing of clone 6D1 in the
liver metastasis of LAU 155 (Figure 3, upper raw). This
spontaneous local T-cell response may have been boosted by
IL-2 and IFN-g that were infused together with chemotherapy,
consistent with the previously proposed effect of systemic
administration of IL-2 in tumor regression by direct activation
of resident tumor antigen-specific T cells naturally present at
tumor site (Monsurro et al., 2003). Moreover, the presence of
clone 6D1 in the cicatricial tissue, after the disappearance of
tumor cells, suggests its role in a local defense against their
resurgence, as a remaining bastion of adaptive immunity.
This corroborates the findings of Masopust et al. (2001), who
showed in a murine model that antigen-specific CD8þ
T cells migrate to non-lymphoid tissues and remain there as
long-lived memory cells. Like Schrama et al. (2003) who
reported the persistence of clonotypes of undefined specifi-
city within sequential sentinel lymph node biopsies, we
found clonotype 15 in two metastases arising 9 years apart.
However, lymph node metastases have been shown to be an
immunosuppressive microenvironment (Lee et al., 2005), so
that detection of clone 15 in this location does not necessarily
imply its efficiency in controlling the tumor in vivo.
Time of induction of a CTL response is an additional point
highlighted by the tracking of clone 15 in LAU 50. Indeed,
this clone was detectable neither in the blood nor in tissues
(primary tumor, in transit metastases and tumor-free lymph
nodes) before treatment by ILP of Melphalan, TNFa and IFNg.
This treatment has been shown to induce apoptosis of the
tumor cells (Ruegg et al., 1998) and significant inflammatory
response (Schienk et al., 1995), two conditions that favor the
induction of an antitumor immune response, which possibly
explains the emergence of clone 15 at this time. A similar
phenomenon has been reported by others who described the
induction of new tumor-specific T-cell clones after electro-
chemotherapy/IL-2 (Andersen et al., 2003). In LAU 155, the
lack of blood or tumor samples before the metastatic process
does not allow us to precisely determine the time of induction
of clone 6D1. Nevertheless, as clone 6D1 was present in the
liver metastasis before chemo-immunotherapy (Figure 3), this
treatment cannot account for the induction of this clone, but
may have stimulated its functions.
In summary, we showed that efficient tumor-reactive
clones persisted over many years in two long-term survivor
metastatic melanoma patients. The localization of these
clones in tumor tissues, their persistence in situ, as well as
their proliferation and effector phenotype during acute phases
of the disease strongly suggest their contribution in tumor
control. However, it is unlikely that the extended survival of
our patients was solely due to this clonal response against
A2/MAGE-A10. Multiple factors are likely to have played a
role. The occurrence of vitiligo in LAU 155 revealed an
immune response against melanocyte-specific antigens such
as Melan-A or tyrosinase. In LAU 50, indeed, we observed
reactivity against other melanoma-associated antigens (i.e.
Melan-A, NY-ESO-1) (data not shown and Valmori et al.,
2000), and non-immunological factors may also have
influenced the clinical course of these patients.
MATERIALS AND METHODS
Patients
Patients LAU 50 and LAU 155 are two HLA-A2þ melanoma patients
with histologically proven metastatic disease that entered in
complete remission after loco-regional chemotherapy, and surgery
(LAU 50) or biochemotherapy (LAU 155) (see ‘‘Results’’). The
Institutional Review Board has approved this study, and clinical
investigation was conducted according to the Declaration of
Helsinki Principles. Informed consent was obtained from both
patients.
T-cell clones and PBMC
Polyclonal and monoclonal MAGE-A10-specific CD8þ T-cell
populations were obtained from melanoma patients as previously
described (Dutoit et al., 2001). Clones LAU 50/15 and LAU 155/6D1
were obtained from peptide MAGE-A10254–262 stimulated CD8
þ
T cells from peripheral blood of melanoma patients LAU 50 and LAU
155, respectively (Dutoit et al., 2001, 2002). Clone 15 was also
obtained from expansion of tumor-infiltrated lymph nodes, after
limiting dilution, as described previously (Dietrich et al., 2001).
Briefly, tumor-infiltrated lymph node cell suspensions, prepared
from a metastatic lymph node, were cultured for 2 weeks in
complete culture medium supplemented with recombinant IL-2 and
recombinant IL-7. MAGE-A10254–262-specific cells were then iso-
lated by multimer-guided sorting and expanded under limiting
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dilution conditions, in the presence of allogeneic PBMC and
phytohaemagglutinin A.
Blood cells and flow cytometry analysis/sorting
PBMCs from both patients, obtained at different time points, were
isolated by centrifugation over a Ficoll–Paque gradient and
cryopreserved in Roswell Park Memorial Institute 1640 medium,
40% fetal calf serum and 10% DMSO. Anti-CD8, anti-CD3-FITC,
and goat-anti-rat IgG-APC were purchased from BD Biosciences
(San Jose, CA) and anti-CD45RA from Immunotech (Nyon, Switzer-
land). Anti-CCR7 rat IgG2a mAb 3D12 was provided by Martin Lipp
(Max Delbrueck-Center for Molecular Medicine, Berlin, Germany).
Multicolor stainings were performed with anti-CD3-FITC, anti-
CD45RA-ECD, anti-CD8-APC-Cy7 reagents, and anti-CCR7 mAb
followed by goat-anti-rat IgG-APC antibody. Briefly, CD8þ T cells
were enriched using a MiniMACS device (Miltenyi Biotec, Bergisch
Gladbach, Germany) resulting in 490% CD3þCD8þ cells. Cells
(106) were incubated with antibodies for 30 minutes at 41C. A total of
5 105 CD8þ T cells/sample were acquired for analysis and/or
specific subsets were sorted with a FACSVantage SETM machine,
and data analyzed with CellQuest software (BD Biosciences,
San Jose, CA).
Histology and immunohistochemistry
Sections (3 mm) of formalin-fixed, paraffin-embedded tissue samples
were immunostained with anti-CD8 mAb (clone C8/144B, Dako-
Cytomation, Basel, Switzerland) after microwave oven antigen
retrieval. Sections were incubated with peroxydase-conjugated
Mouse-Envision (DakoCytomation) and staining was visualized with
3,30-diaminobenzidine solution. Sections were counterstained with
hemalun.
Amplification, spectratyping, and sequencing of TCR transcripts
Total RNA was extracted from PBMC or sorted cells using RNeasy
mini kits (Qiagen, Hilden, Germany) from 102 to 106 cells.
First strand cDNA was synthesized using oligodT and reverse
transcriptase Superscript II (Invitrogen, Paisley, UK) in a 20 ml final
volume. cDNA samples were PCR amplified in parallel using a panel
of 24 BV-specific oligonucleotides as forward primers, and a TCR
b-chain constant region (BC)-specific oligonucleotide as reverse
primer in a 40-cycle PCR. CDR3 length analysis (spectratyping) and
sequencing were performed as described previously (Dietrich et al.,
2001). The TCR nomenclature proposed by Arden et al. (1995) was
adopted.
Molecular detection and quantification of T-cell clonal
frequency
Total RNA from peripheral CD8þ T cells and frozen tissues was
extracted using Qiagen Rneasy mini kit, treated with DNase I
(Qiagen) to eliminate possible genomic contamination, and reversed
transcribed with oligodT as described above. Total RNA from
formalin-fixed and paraffin-embedded tissues was extracted using
the Optimum FFPE RNA Isolation kit (Ambion, Austin, TX), and
reversed transcribed with a primer specific for the TRBC (Vely et al.,
2001) or for the TCR-BV21 chain (Genevee et al., 1992).
For qRT-PCR, oligonucleotide primers and probes specific
for clonotypes or for the normalizer TRBC were designed using
Primer Express software (Applied Biosystems, Rotkreuz, Switzerland)
and synthesized by Eurogentec (Seraing, Belgium) and Applied
Biosystems. TRBC (forward) CAAACCTGTCACCCAGATCGT,
(reverse) AGGTGAAGCCACAGTCTGCTCTA, (MGB-probe) 6-FAM
AGCGCCGAGGCCT-MGB; clone LAU 50/15 (forward) TTTGGGG
GGCTGGGCTAC, (reverse) GAACACGTTTTTCAGGTCCTCTGT,
(probe) FAM-AGCAGTACTTCGGGCCGGGCAC-TAMRA; clone
LAU 155/6D1 (forward) TGTGCCAGCAGCTTAGAATACAC, (reverse)
CCTCCAGTACGGTCAGCCTAGA, (MGB-probe) 6FAM-AGCTGT
TTTTTGGAGAAGG-MGB. TRBC primers were designed to span
exon–intron junctions and significant homologies between CDR3
rearrangements and genomic sequences were excluded by running
searches on the GenBank database. Purity of RNA was controlled on
agarose gels to confirm the absence of genomic DNA. During
optimization of real-time PCR conditions, amplified products were
purified (E.Z.N.A. Cycle-Pure kit, PeqLab, Erlangen, Germany),
cloned using TOPO-TA cloning kit (Invitrogen) and sequenced with
the M13 primer.
Quantification: Reverse transcriptase-PCR products of clone LAU
50/15 and clone LAU 155/6D1 amplified with BV21 and Cbc
primers (Genevee et al., 1992) were cloned using TOPO-TA cloning
kit (Invitrogen). Incorporation was confirmed by sequencing.
Clonotype 15 and 6D1 plasmids were serially 1:10 diluted to
generate standard curves as references for the quantification of target
molecules in each sample. Clonotypic mRNA quantity was normal-
ized on the quantity of transcripts of the TRBC. To quantify this
normalizer, serial dilutions of cDNA from CD8þ T-cell clones were
used to generate TRBC standard curves. Results are expressed as the
ratio of clonotype/TRBC mRNA quantity. For all experiments, real-
time quantitative reverse transcriptase-PCR was performed on an
ABI-7700 Sequence Detection System (Applied Biosystems), using
the qPCR MasterMix (Eurogentec) according to the manufacturer’s
recommendations. All reactions were run in duplicate or triplicate,
and results were confirmed by at least one additional independent
run. For each set of clonotypic primers/probe, background level of
PCR amplification was assessed on PBMC from seven healthy donors
and two melanoma patients who had no MAGE-A10-specific
response. A background threshold was determined by the mean of
these results plus 2 SD.
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